SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff and Goldman Sachs Buy upgrade are driving discussion, but the upgrade-fueled bounce quickly faded as traders focused on the companys heavy debt, borrowing costs, and ability to finance its AI infrastructure expansion. Dip buyers see an oversold setup and possible short squeeze, while bears warn of further losses or dilution if financing remains difficult.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is dominating discussion, with traders pointing to weak housing and roofing demand, high rates, and analyst target cuts as pressures on the building-products roll-up. Many criticize perceived dilution and managements limited communication, while some long-term holders argue the selloff is excessive and continue buying.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

HOOD is drawing attention for a steep selloff, with traders pointing to analyst caution and target cuts, broader risk-off conditions, and weakness in crypto-related stocks as possible pressures ahead of earnings. The conversation is split between fears of further losses and dip-buying hopes that support will hold and the stock can recover.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention for its steep slide to new lows, with many traders criticizing the companys business fundamentals and treating it as a Trump-linked meme stock; political fortunes and the approaching midterms are also cited as potential overhangs. Some traders still frame the depressed share price and merger or fusion prospects as a speculative opportunity.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid scheduled IPO lockup share releases, concerns about insider selling, and a TD Cowen price-target cut; traders also debate whether valuation, growth and OpenAI customer concentration leave room for further downside. Most discussion is bearish and frustrated, though some investors see the selloff as an oversold buying opportunity based on Cerebrass AI-chip potential.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs steep, persistent selloff and weak performance despite relatively resilient Bitcoin are dominating discussion, with traders pointing to skepticism over the AI/data-center pivot and the lack of signed tenant contracts. Frustrated bears cite management and execution concerns, while some bulls view the decline as overdone and anticipate a rebound if Bitcoin strengthens or a lease is announced.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of CorMedixs supplemental application for REZZAYO prophylaxis with Priority Review is driving attention, putting a decision on the expanded indication on the regulatory path. Traders see potential for a broader growth opportunity, but some are frustrated that the news has not produced a stronger share-price response; approval is not assured.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLOs steep decline is being discussed alongside concerns about ongoing share dilution, limited company updates, and a long path to licensing and revenue, with traders also pointing to weakness across speculative nuclear stocks. Some see the selloff as an oversold entry tied to long-term nuclear power demand, while others question the companys valuation and ability to execute.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertins Phase 3 APOLLO trial met both co-primary and all secondary endpoints in erythropoietic protoporphyria, addressing efficacy questions behind the FDAs earlier rejection; the company plans to resubmit its application. Traders are debating whether the positive data can sustain the rally, with profit-taking and selling pressure competing against bullish views and speculation about a short squeeze.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus shares are drawing attention for their steep selloff and fresh lows, with traders frequently blaming share dilution and questioning the valuation and funding needs of its capital-intensive enrichment expansion. Some see the decline as an opportunity based on long-term U.S. nuclear-fuel demand, while others remain concerned about further downside and execution risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Equity

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold

Wall Street Zen raised Century Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...

Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

What is HC Wainwright's Estimate for IPSC Q1 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Century Therapeutics in a research note issued on...

Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been given an average recommendation of "Hold" by the seven ratings firms that are presently covering the stock, Marketbeat.com reports...

Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,289,543 shares, an increase of 19.3% from the March 15th total of 8,626,834 shares. Based on an average daily volume...

Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 8,626,834...

Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Moderate Buy" by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, Marketbeat...

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Century Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Lilly will present Phase 2 results for its eloraTZP combination at the EASD meeting in Milan.</li><li>SAB BIO, Sana and Century will present type 1 diabetes research at different stages of development.</li><li>uniQure expects a four-year AMT-130 update by quarter-end and Scynexis has guided to two Phase 1 updates.</li></ul><p>Biotech investors face a crowded final week of September as Eli Lilly (LLY) and Novo Nordisk (NVO) bring their latest obesity and diabetes research to a major medical meeting in Milan, while uniQure (QURE) and Scynexis (SCYX) approach quarter-end targets for clinical updates that could put smaller stocks in the spotlight.&nbsp;</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 1.8% last week, outperforming the broader market’s<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which rose 1.3%, but trailing the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, which climbed 3.3%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> advanced 2.6%, beating both <a class="mention" data-mention="$XLV" data-symbol-id="XLV" href="https://stocktwits.com/symbol/XLV" target="_blank">XLV</a> and SPY while lagging QQQ. The<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.1%.&nbsp;</p><p><img src="https://news.stocktwits-cdn.com/healthcare_fef01ed028.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/ Event</td><td>Development</td></tr><tr><td>Sept.28</td><td>CAMP</td><td>Camp4 Therapeutics holds an analyst day on its CMP-002 trial for SYNGAP1-related disorder.</td></tr><tr><td>Sept.28-Oct.2</td><td>EASD</td><td>Lilly, Novo and smaller biotech companies present diabetes and obesity research in Milan.</td></tr><tr><td>Sept.29</td><td>NVO, KURA</td><td>Novo presents CagriSema analyses, while Kura affiliate Caspian Therapeutics presents preclinical KO-7246 research.</td></tr><tr><td>Sept.30</td><td>LLY, NVO, SABS</td><td>Lilly presents Phase 2 eloraTZP results; Novo has several pipeline sessions; SAB BIO discusses SAB-142.</td></tr><tr><td>By Sept.30</td><td>QURE, SCYX</td><td>Potential four-year AMT-130 update from uniQure and two Phase 1 topline updates from Scynexis.</td></tr><tr><td>Oct.1</td><td>LLY, FDA</td><td>Lilly presents Foundayo data; an FDA panel discusses influenza vaccine strain selection.</td></tr><tr><td>Oct.2</td><td>SANA, IPSC</td><td>Sana and Century present separate type 1 diabetes cell-therapy programs.</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Lilly, Novo Put Next Obesity Drugs On Display&nbsp;</strong></h2><p>The European Association for the Study of Diabetes’ annual meeting runs Monday through Friday in Milan, with obesity and diabetes presentations from Eli Lilly and Novo Nordisk. The program also includes type 1 diabetes research from SAB BIO (SABS), Sana Biotechnology (SANA) and Century Therapeutics (IPSC).<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.easd.org/annual-meeting/?utm_source=chatgpt.com">&nbsp;</a></p><p>On Wednesday, Lilly will present Phase 2 results for eloraTZP, a combination of the amylin-targeting drug Eloralintide and Tirzepatide, the ingredient in Mounjaro and Zepbound. The study involves adults with obesity or overweight and type 2 diabetes. Lilly will also discuss Phase 3 findings for Retatrutide, which targets three hormone receptors, and results from Surpass-CVOT, a study of Tirzepatide’s cardiovascular outcomes. Thursday’s session covers Phase 3 findings for its oral diabetes drug Foundayo, or Orforglipron. Lilly has already disclosed headline results from several of these studies and the presentations will add more details.</p><p>Novo has 44 abstracts at the meeting. Tuesday’s presentations include Reimagine 1 analyses of CagriSema’s effects on body composition and combined blood-sugar and weight-loss goals. On Wednesday, Novo will discuss CagriSema’s effects on appetite and responses to food cues, and present Phase 2b results for Zenagamtide, also known as Amycretin.</p><h2 class="st-heading-2"><strong>Smaller Biotechs Target Type 1 Diabetes&nbsp;</strong></h2><p>SAB BIO (SABS) will present research on SAB-142, an immunotherapy for type 1 diabetes, on Monday and Wednesday. Its Phase 1 findings address repeat dosing and early C-peptide signals. C-peptide helps show how much insulin a patient’s body still produces.</p><p>Friday features two cell-therapy programs at different stages. Sana Biotechnology (SANA) will discuss findings from a first-in-human study involving engineered donor insulin-producing cells transplanted into one patient without immunosuppressive drugs. Century Therapeutics (IPSC) will present preclinical research on manufacturing engineered stem-cell-derived insulin-producing cells for its CNTY-813 program.&nbsp;</p><p>Kura Oncology (KURA) is also linked to the diabetes program. Its separately financed affiliate, Caspian Therapeutics, will present Tuesday on KO-7246, an experimental drug being studied for its potential to increase insulin-producing beta cells.&nbsp;</p><h2 class="st-heading-2"><strong>Beyond Milan: 3 More Events To Watch This Week&nbsp;</strong></h2><p>Sellas Life Sciences (SLS) is also in focus as the AACR pancreatic-cancer conference concludes on Monday. The company released preclinical findings on its experimental drug SLS009 on Friday, ahead of three poster presentations&nbsp;that happened on Sunday. The studies examined SLS009 in pancreatic-cancer models, including combinations designed to address treatment resistance.</p><p>Camp4 Therapeutics (CAMP) has a confirmed event on Monday. Its analyst day will cover the design of a first-in-human Phase 1/2 trial of CMP-002 for Syngap1-related disorder. CAMP4 expects to start the trial in the fourth quarter.</p><p>Meanwhile, the FDA’s vaccine advisory committee is scheduled to meet on Thursday to recommend influenza virus strains for vaccines intended for the 2027 Southern Hemisphere season. Its recommendations are nonbinding.</p><h2 class="st-heading-2"><strong>Quarter-End Data Clock Ticks For QURE, SCYX&nbsp;</strong></h2><p>Outside the conference, uniQure (QURE) intends to present a four-year analysis of its AMT-130 gene-therapy studies in Huntington’s disease before the third quarter ends on Wednesday. The firm’s earlier guidance said the update would include four years of follow-up on 24 patients in its first two treatment cohorts.&nbsp;</p><p>uniQure submitted AMT-130 applications to U.S. and U.K. regulators earlier this month, supported by an earlier three-year analysis. The pending four-year update is a separate milestone. The company has requested priority review in the U.S.</p><p>Additionally, Scynexis (SCYX) has guided to two Phase 1 topline updates in the third quarter. Results for SCY-770, a potential treatment for inherited polycystic kidney disease, are expected to help select doses for a Phase 2 study. The other update concerns an intravenous version of SCY-247, an experimental antifungal.&nbsp;</p><h2 class="st-heading-2"><strong>Moderna’s Melanoma Details Remain Pending&nbsp;</strong></h2><p>Moderna (MRNA) and Merck (MRK) announced in August that their Phase 3 INTerpath-001 trial met its goals for delaying melanoma recurrence and the spread of cancer to distant parts of the body. The trial tested Moderna’s individualized cancer treatment Intismeran with Merck’s Keytruda after patients’ tumors had been surgically removed.&nbsp;</p><p>Investors are still awaiting the detailed results. The companies plan to present them at an “international medical meeting,” but have not named the conference or date.&nbsp;</p><h2 class="st-heading-2"><strong>LLY, NVO, QURE: How Do Retail Traders Feel?</strong></h2><p>Retail traders on Stocktwits turned more upbeat on LLY and QURE, even as chatter cooled. Sentiment on LLY improved to ‘neutral’ from ‘bearish’ over the past week, while message volume fell 10%. QURE sentiment rose to ‘bullish’ from ‘neutral’ a week ago, despite a 33% drop in 24-hour message volume.&nbsp;</p><p>NVO drew the most optimistic response: sentiment was ‘extremely bullish’ as message volume surged 100% over the past week.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stla-f-gm-trump-fuel-economy-rollback-auto-plants-coming-back/cZMSWm8RBfh">STLA, F, GM Climb Overnight As Trump Clears Fuel Economy Rollback — Says Auto Plants Are ‘Coming Back’&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch

iShares Biotechnology ETF

Lilly(Eli) & Co

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

uniQure NV

SAB Biotherapeutics Inc

Sana Biotechnology Inc

Scynexis Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$1.50
Prev Close	$1.37
Open	$1.39
Dividend Yield	0.00%
50-Day Moving Average	$1.83
Beta	1.62
Avg. Volume	484,379.82
PE Ratio	-1.53

52-Week High	$3.04
52-Week Low	$0.435
Market Capitalization	$248.07M
EPS (Annual)	-$0.1107
Price to Book	1.06
Revenue Per Employee	$1.4M

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPSC Fundamentals